Ruxandra Draghia-Akli
CIK 2041719 · View on SEC EDGAR ↗
First SEC filing: March 9, 2026 · Latest: March 9, 2026
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 3, 2026 | NVAX | D | 26,667 | — | — | 53,333 Direct | -33.33% | Disposed | (price as of 2026-08-21) |
| March 3, 2026 | NVAX | F | 11,313 | $9.49 | $107,360 | 23,563 Direct | -32.44% | Disposed | -6.8% (price as of 2026-08-21) |
| March 3, 2026 | NVAX | M | 26,667 | — | — | 34,876 Direct | +324.85% | Acquired | (price as of 2026-08-21) |
| March 2, 2026 | NVAX | A | 139,500 | — | — | 139,500 Direct | — | Acquired | (price as of 2026-08-21) |
| March 2, 2026 | NVAX | A | 139,500 | $9.09 | $1,268,055 | 139,500 Direct | — | Acquired | -2.7% (price as of 2026-08-21) |
| March 2, 2026 | NVAX | A | 93,000 | — | — | 101,000 Direct | +1162.50% | Acquired | (price as of 2026-08-21) |
| Nov. 11, 2025 | NVAX | D | 14,257 | — | — | 28,513 Direct | -33.33% | Disposed | (price as of 2026-08-21) |
| Nov. 11, 2025 | NVAX | F | 6,048 | $7.40 | $44,755 | 8,209 Direct | -42.42% | Disposed | 19.5% (price as of 2026-08-21) |
| Nov. 11, 2025 | NVAX | M | 14,257 | — | — | 14,257 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 3, 2026 | NVAX | Restricted Stock Units | Common Stock (26,667) | $0.00 | March 3, 2035 | 26,667 | Disposed |
| March 2, 2026 | NVAX | Non-Statutory Stock Option NQ | Common Stock (139,500) | — | March 2, 2036 | 139,500 | Acquired |
| March 2, 2026 | NVAX | Non-Statutory Stock Opotion NQ | Common Stock (139,500) | $9.09 | March 2, 2036 | 139,500 | Acquired |
| March 2, 2026 | NVAX | Restricted Stock Units | Common Stock (93,000) | $0.00 | March 2, 2036 | 93,000 | Acquired |
| Nov. 11, 2025 | NVAX | Restricted Stock Units | Common Stock (14,257) | — | Nov. 11, 2034 | 14,257 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
NVAX
M.D., Ph.D.Former EVP, Head of Research& Development| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $600,000 | — | — | — | $290,250 | — | $115,490 | $2,303,380 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.